| Somatostatin-Producing Neuroendocrine Tumor studied in …STUDIED_INderived17 of 17show fewer |
|---|
| → studied in | NCT01824875Phase 2 · completed Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00655655Phase 1 · completed Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01525082Phase 2 · completed Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02031536Phase 2 · terminated Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02259725Phase 2 · completed Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01869725Phase 2 · completed Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01465659Phase 1/Phase 2 · completed Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Malignant Pancreatic Somatostatinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00454363Phase 2 · completed Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer · condition mapped ONTOLOGY_EXACT · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01010126Phase 2 · completed Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer · condition mapped ONTOLOGY_EXACT · 17 trials mapped (0 active) | — | — | Malignant Pancreatic Somatostatinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02831179Phase 1 · withdrawn Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor · condition mapped ONTOLOGY_EXACT · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02108782Phase 2 · withdrawn Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02273752Phase 2 · terminated Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01204476Phase 1 · completed Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma · condition mapped ONTOLOGY_EXACT · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00131911Phase 2 · completed Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00075439Phase 2 · completed Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00084461Phase 2 · terminated Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00004074Phase 1 · completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu · condition mapped ALIAS · 17 trials mapped (0 active) | — | — | Somatostatin-Producing Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |